Therapy News and Research

RSS

Chinese sFDA approves Baxter's ADVATE to treat hemophilia A

Baxter International Inc. today announced the approval of ADVATE [Recombinant Human Coagulation Factor VIII for injection] for the control and prophylaxis of bleeding episodes in individuals with hemophilia A (congenital factor VIII deficiency) in China by the State Food and Drug Administration.

From Baxter International Inc. 17 May 2012

Combination of daclizumab and vaccine improves survival of breast cancer patients

A team from the Perelman School of Medicine and the Abramson Family Cancer Research Institute at the University of Pennsylvania found that the FDA-approved drug daclizumab improved the survival of breast cancer patients taking a cancer vaccine by 30 percent, compared to those patients not taking daclizumab.

17 May 2012

Stroke survivors from King County to share their stories during EMS Week

Hours, or even minutes, can mean the difference between life and death when someone is having a stroke. As part of Emergency Medical Services (EMS) Week from May 20-26, stroke survivors from King County will share their stories about how quick recognition of stroke symptoms and timely response and treatment through King County EMS helps patients survive and return to full health.

17 May 2012

Dialysis patients can benefit from talking control support therapy

The constant health education that dialysis patients receive can lead to boredom and noncompliance. But a Loyola University Medical Center study has found that brief, casual chats can be a significant benefit to patients.

17 May 2012

May issue of NeuroPerspective assesses field of stroke therapeutics

NeuroPerspective, the independent, monthly review of the neurotherapeutics area, has released its May issue, which assesses the field of therapeutics for stroke.

17 May 2012

Results from Boehringer Ingelheim’s LUX-Lung 3 Phase III trial on stage IIIB or IV NSCLC

Boehringer Ingelheim will present results from LUX-Lung 3, the company's pivotal Phase III clinical trial investigating afatinib in patients with stage IIIB or IV non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation (EGFR M+), at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 1-5, 2012.

17 May 2012

New directions and challenges in viral hepatitis care and research

The editors of Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute, are pleased to announce the publication of this year's highly anticipated special 13th issue. Published each May, the 13th issue is devoted to a particular gastroenterological topic of broad interest; this year's topic is viral hepatitis.

16 May 2012

New insight into treatment patterns for people with stage two and three rectal cancer

Research from the University of Alberta provides new insight into treatment patterns for people with stage two and three rectal cancer-information that ultimately will help physicians improve care strategies for patients provincewide.

16 May 2012

Some hand function restored in quadriplegic patient with spinal cord injury

Surgeons at Washington University School of Medicine in St. Louis have restored some hand function in a quadriplegic patient with a spinal cord injury at the C7 vertebra, the lowest bone in the neck. Instead of operating on the spine itself, the surgeons rerouted working nerves in the upper arms. These nerves still "talk" to the brain because they attach to the spine above the injury.

16 May 2012

Dual prevalence of STIs/RTIs and malaria in pregnancy found among women in sub-Saharan Africa

A review of studies reporting estimates of the prevalence of sexually transmitted infections/reproductive tract infections (STIs/RTIs) and malaria over the past 20 years suggests that a considerable burden of malaria and STIs/RTIs exists among pregnant women attending antenatal (before birth) facilities in sub-Saharan Africa, according to a review and meta-analysis of previous studies published in the May 16 issue of JAMA, a theme issue on Global Health.

16 May 2012

First patient included in the phase II study of Amphinex® in head and neck cancer patients

PCI Biotech (PCIB) the Norwegian biopharmaceutical company, reported today that the first patient has been included in the phase II study of Amphinex in combination with the cytotoxic agent bleomycin in head and neck cancer patients, called the ENHANCE study. The first patient was included at the National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Germany. NCT is a joint project of the German Cancer Research Center (DKFZ), Heidelberg University Hospital, Thoraxklinik Heidelberg and Deutsche Krebshilfe (German Cancer Aid).

16 May 2012

Achaogen’s plazomicin and levofloxacin safe and effective in treating cUTI, acute pyelonephritis

Achaogen, Inc. announced today that all objectives were met in the company's multi-national Phase 2 study of plazomicin compared to levofloxacin for the treatment of complicated urinary tract infections (cUTI) and acute pyelonephritis in adults.

16 May 2012

Sorin receives PMDA authorization to market MEMO 3D ring

Sorin Group, a global medical device company and a leader in the treatment of cardiovascular diseases, announces that it received authorization from the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) to market its MEMO 3D Semi-Rigid Annuloplasty Ring.

16 May 2012

Combination of vaccine and letrozole effectively improves survival from breast cancer

A vaccine that targets cancer cells in combination with the drug letrozole, a standard hormonal therapy against breast cancer, significantly increased survival when tested in mice, a team of UC Davis investigators has found.

16 May 2012

Thermo Fisher signs asset purchase agreement with Nephromics for PlGF assay

Thermo Fisher Scientific Inc., the world leader in serving science, today announced it has signed an asset purchase agreement with Nephromics LLC, which includes a patent license for exclusive rights to use PlGF for the diagnosis of pre-eclampsia or eclampsia. Clinical trials have shown that PlGF supports the diagnosis and risk prediction for preeclampsia.

From Thermo Fisher Scientific Inc. 16 May 2012

Pfizer fails to meet primary endpoint in TORISEL Phase 3 study for advanced RCC

Pfizer Inc announced that the Phase 3 INTORSECT (B1771003) study, evaluating TORISEL(temsirolimus) in patients with advanced renal cell carcinoma (RCC) whose disease had progressed on or after SUTENT (sunitinib malate) therapy, did not meet the primary endpoint of prolonging progression free survival (PFS) when compared to sorafenib.

16 May 2012

Galectin Therapeutics commences Phase 1/2 trial of new treatment combination for advanced MM

Galectin Therapeutics, the leader in developing carbohydrate-based therapeutic compounds to inhibit galectin proteins for the therapy of liver fibrosis and cancer, today announced that the first patient has been dosed in a Phase 1/2 trial evaluating the safety and efficacy of a novel treatment combination for the treatment of advanced metastatic melanoma.

16 May 2012

Juventas begins enrollment in JVS-100 Phase IIa study for Rutherford Class 4 or 5 CLI

Juventas Therapeutics, a privately-held, clinical-stage company developing novel regenerative therapies for treatment of cardiovascular disease, is pleased to report that it is actively enrolling patients in a placebo-controlled, randomized double-blinded Phase IIa study evaluating the safety and efficacy for JVS-100 in patients with Rutherford Class 4 or 5 critical limb ischemia.

16 May 2012

Svelte completes enrollment in DIRECT drug-eluting stent study

Svelte Medical Systems today announced completion of enrollment in the DIRECT (Direct Implantation of Rapamycin-eluting stent with bio-Eroding Carrier Technology) study conducted at four investigational sites in New Zealand.

15 May 2012

Cyclophosphamide drug makes the bone marrow more tumor-friendly

Researchers found that administering a common chemotherapy drug before bone tumors took root actually fertilized the bone marrow, enabling cancer cells, once introduced, to seed and grow more easily.

15 May 2012

Therapy News and Research

Chinese sFDA approves Baxter's ADVATE to treat hemophilia A

Combination of daclizumab and vaccine improves survival of breast cancer patients

Stroke survivors from King County to share their stories during EMS Week

Dialysis patients can benefit from talking control support therapy

May issue of NeuroPerspective assesses field of stroke therapeutics

Results from Boehringer Ingelheim’s LUX-Lung 3 Phase III trial on stage IIIB or IV NSCLC

New directions and challenges in viral hepatitis care and research

New insight into treatment patterns for people with stage two and three rectal cancer

Some hand function restored in quadriplegic patient with spinal cord injury

Dual prevalence of STIs/RTIs and malaria in pregnancy found among women in sub-Saharan Africa

First patient included in the phase II study of Amphinex® in head and neck cancer patients

Achaogen’s plazomicin and levofloxacin safe and effective in treating cUTI, acute pyelonephritis

Sorin receives PMDA authorization to market MEMO 3D ring

Combination of vaccine and letrozole effectively improves survival from breast cancer

Thermo Fisher signs asset purchase agreement with Nephromics for PlGF assay

Pfizer fails to meet primary endpoint in TORISEL Phase 3 study for advanced RCC

Galectin Therapeutics commences Phase 1/2 trial of new treatment combination for advanced MM

Juventas begins enrollment in JVS-100 Phase IIa study for Rutherford Class 4 or 5 CLI

Svelte completes enrollment in DIRECT drug-eluting stent study

Cyclophosphamide drug makes the bone marrow more tumor-friendly

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News